Renal Anemia Treatment Market By Treatment Type (Erythropoiesis-Stimulating Agents, Iron Supplements [Oral Iron, Intravenous Iron], HIF-Prolyl Hydroxylase Inhibitors, Red Blood Cell Transfusions, Hepcidin-Targeted and Anti-Inflammatory Therapies, Other Supportive Treatments); By Application (Non-Dialysis-Dependent Chronic Kidney Disease, Hemodialysis-Dependent Chronic Kidney Disease, Peritoneal Dialysis-Dependent Chronic Kidney Disease, ESA-Hyporesponsive Renal Anemia, Iron-Deficiency and Iron-Restricted Renal Anemia); By End User (Hospitals, Dialysis Centers, Nephrology Clinics, Ambulatory Infusion Centers, Homecare Settings, Retail and Specialty Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Renal Anemia Treatment Market: Pre-Dialysis Treatment Gaps and Oral HIF-PHI Access Shift Value Beyond Injectable ESAs

The Global Renal Anemia Treatment Market was valued at USD 6.29 billion in 2025 and is projected to reach USD 9.84 billion by 2032, growing at a CAGR of 6.6%, according to Strategic Market Research.

 

The Renal Anemia Treatment Market is moving away from a dialysis-centred model in which injectable erythropoiesis-stimulating agents account for most treated volume. The larger growth opportunity now sits before dialysis, where anemia is common but iron therapy, ESAs, and specialist monitoring remain underused. KDIGO’s 2026 guideline strengthens this shift by placing iron correction before erythropoietic treatment and recommending the lowest effective ESA exposure within a haemoglobin ceiling below 11.5 g/dL.

 

Injectable ESAs will remain central to haemodialysis care because dialysis facilities already control laboratory monitoring, administration, reimbursement, and purchasing. Revenue expansion, however, increasingly depends on intravenous iron protocols that reduce ESA dose, oral HIF-prolyl hydroxylase inhibitors that fit dialysis workflows or reach non-dialysis patients, and pipeline therapies directed at hepcidin-mediated iron restriction.

 

The commercial test for a new renal anemia treatment is no longer whether it raises haemoglobin. Suppliers must show that the product reduces transfusions, lowers ESA requirements, maintains haemoglobin within a narrow target, works in inflammation-driven anemia, or reaches patients who are currently untreated.

 

The Largest Patient Pool Is Outside the Mature Dialysis Segment

Global CKD prevalence reached an estimated 788 million adults in 2023, more than double the 378 million recorded in 1990. The age-adjusted prevalence was 14.2% among adults aged 20 years and older. Only part of this population develops clinically relevant renal anemia, but a 2025 burden analysis still estimated 63.75 million prevalent cases of anemia attributable to CKD in 2021, up 96.2% from 1990. Population ageing accounted for much of the increase in absolute cases.

Treatment demand narrows sharply after CKD stage, haemoglobin, iron status, symptoms, cardiovascular risk, cancer history, and reimbursement eligibility are considered. NIDDK estimates that more than one in seven Americans with kidney disease has anemia, while most people with kidney failure are affected. The clinically treated population is therefore concentrated in advanced CKD rather than distributed evenly across the broader kidney-disease pool.

A 2025 systematic review covering 86 Asian studies, ten countries, and more than 1.34 million participants estimated anemia prevalence at 42% across CKD populations and about 80% in stage 5 disease. ESA treatment averaged 40%, while iron treatment averaged 21%. ESA use ranged from 7%–29% before kidney failure and 63%–95% in kidney failure, confirming that treatment intensity rises sharply after patients enter dialysis or approach it.

The 6,766-patient CKDopps study found that 42%–53% of anemic patients attending nephrology clinics in Brazil, France, Germany, and the United States had ferritin below 100 ng/mL or transferrin saturation below 20%. Only 27% of affected patients in France and just over 40% in the other three countries received iron within three months. Among patients with haemoglobin below 10 g/dL, ESA use ranged from 28% in the United States to 57% in Germany.

Non-dialysis CKD therefore contains a larger unconverted patient pool than the highly treated haemodialysis segment. Growth depends on earlier ferritin and transferrin-saturation testing, more consistent nephrology referral, and reimbursement before patients require transfusion or dialysis.

 

KDIGO 2026 Moves Iron Testing Ahead of ESA Escalation

KDIGO’s 2026 guideline places iron status at the beginning of the treatment pathway. For haemodialysis patients, iron initiation is suggested when ferritin is at or below 500 ng/mL and transferrin saturation is at or below 30%. A proactive maintenance strategy is preferred over reactive replacement because stable iron availability may improve cardiovascular outcomes and reduce treatment variability.

Patients not receiving haemodialysis have different thresholds. Iron treatment is suggested when ferritin is below 100 ng/mL with transferrin saturation below 40%, or when ferritin is 100–300 ng/mL with transferrin saturation below 25%. Routine treatment is generally withheld when ferritin exceeds 700 ng/mL or transferrin saturation reaches 40%.

These thresholds increase recurring demand for complete blood counts, ferritin assays, transferrin-saturation testing, and treatment monitoring. Laboratories and renal-care providers gain from more frequent assessment, while drug selection becomes less dependent on haemoglobin alone.

KDIGO continues to position ESAs ahead of HIF-PHIs as first-line erythropoietic therapy. Dialysis patients are generally considered for ESA initiation when haemoglobin reaches 9–10 g/dL. Non-dialysis initiation is individualized within a broader range, commonly 8.5–10 g/dL, according to symptoms, cardiovascular risk, transfusion risk, and transplant candidacy. ESA-treated adults should remain below 11.5 g/dL.

The haemoglobin ceiling limits dose-led ESA growth. Manufacturers must compete through reduced injection frequency, stable response, lower dose requirements, and predictable facility economics rather than higher haemoglobin targets.

 

Proactive Intravenous Iron Is Reducing ESA Requirements

The PIVOTAL trial established intravenous iron as an active budget and outcome lever in haemodialysis rather than a secondary supplement. Among 2,141 patients, the composite of death, myocardial infarction, stroke, or heart-failure hospitalization occurred in 29.3% of patients receiving proactive higher-dose iron and 32.3% receiving reactive lower-dose iron. The proactive strategy was superior, with a hazard ratio of 0.85, without an increase in infection.

Median monthly ESA use was approximately 29,757 IU in the proactive group and 38,805 IU in the reactive group. A reduction of more than 7,500 IU per month creates a direct substitution effect: additional iron spending can reduce ESA purchasing while improving clinical performance.

FIND-CKD extended the iron opportunity into non-dialysis disease. The trial included 626 patients with CKD, anemia, and iron deficiency who were not receiving ESAs. Another anemia treatment or a protocol-defined low-haemoglobin trigger occurred in 23.5% of patients receiving higher-ferritin intravenous ferric carboxymaltose, compared with 31.8% receiving oral iron. The hazard ratio was 0.65.

Intravenous iron therefore competes against both oral iron and later ESA initiation. Products that delay ESA use, reduce transfusions, or require fewer infusions can defend higher acquisition costs. Oral formulations retain an important position in earlier CKD, but gastrointestinal intolerance, daily adherence, and inflammation-related absorption limits reduce their effectiveness in advanced disease.

Iron manufacturers also face a more evidence-sensitive market. The strongest position belongs to products supported by dosing efficiency and downstream treatment savings rather than formulations differentiated only by elemental iron content.

 

Dialysis Infrastructure Protects ESA Volume Despite Pricing Pressure

Haemodialysis remains the most penetrated renal anemia treatment setting. Regular laboratory assessment and scheduled facility visits allow dialysis organizations to administer ESAs and intravenous iron at scale. Purchasing decisions are concentrated among large providers, making contracts, bundled reimbursement, storage, and dosing frequency major determinants of market share.

USRDS reported that more than three-quarters of U.S. haemodialysis patients received an ESA in early 2023, while treatment was lower among peritoneal-dialysis patients. Severe anemia has not disappeared: the share of haemodialysis patients with haemoglobin below 9 g/dL increased from 5.5% in 2013 to 9.1% in 2023.

Epoetin alfa, darbepoetin alfa, and methoxy polyethylene glycol-epoetin beta remain protected by established protocols and long clinical experience. Biosimilars limit price growth, while proactive iron use reduces dose intensity. Long-acting products can still gain where fewer administrations reduce nursing time or improve control in home dialysis and non-dialysis care.

Genexine and KGbio received Indonesian approval for efepoetin alfa in 2023, creating a regional commercial pathway for a long-acting ESA. A multinational Phase III study is also comparing efepoetin alfa with darbepoetin alfa in haemodialysis patients. The product must show that extended dosing generates operational savings large enough to offset competition from lower-priced ESA products and oral HIF-PHIs.

 

U.S. HIF-PHI Adoption Is Being Decided by Dialysis Contracts

U.S. approvals have restricted oral HIF-PHIs to dialysis-dependent adults. Daprodustat was approved for patients receiving dialysis for at least four months, while vadadustat is approved after at least three months. Neither label covers anemia in non-dialysis CKD, removing the largest undertreated population from the current U.S. addressable market.

GSK withdrew Jesduvroq from the U.S. market after a short commercial period. FDA later determined that the withdrawal was not due to safety or effectiveness. The exit showed that an oral route and regulatory approval do not guarantee a viable franchise when dialysis contracts, reimbursement, and product positioning are weak.

Akebia built Vafseo around dialysis-network access rather than retail prescribing. By early 2026, the company reported access covering approximately 290,000 patients. First-quarter 2026 Vafseo revenue reached USD 15.8 million, compared with USD 12 million in the prior-year quarter. Prescribers increased to approximately 1,025, up 28% from the fourth quarter of 2025, while the number of treated patients increased by about 60% sequentially.

Vafseo’s early uptake is tied to dialysis-organization agreements and temporary Transitional Drug Add-on Payment Adjustment support outside the standard ESRD bundle. Long-term performance will be tested when facilities must absorb the medicine within routine reimbursement. Akebia must show that observed oral dosing, lower administration burden, or stable haemoglobin control offsets the economics of injectable ESAs.

The contrast between GSK’s withdrawal and Akebia’s launch confirms that commercial execution, not oral convenience alone, determines HIF-PHI adoption in the United States.

 

China and India Open the Larger Non-Dialysis HIF-PHI Opportunity

Asian markets allow HIF-PHI suppliers to reach patients excluded from U.S. labels. China approved Zydus Lifesciences’ desidustat in March 2026 for anemia in adults with non-dialysis CKD under an exclusive licensing agreement with China Medical System Holdings. Zydus reported that the Chinese Phase III program met its primary endpoint and maintained haemoglobin within the target range in an extension study.

The Chinese opportunity is commercially relevant because target achievement remains much lower before dialysis than during haemodialysis. Zydus cited haemoglobin-target attainment of 51.5% in haemodialysis patients and 8.2% in non-dialysis CKD patients with anemia. The company also reported that more than 100,000 Indian patients had received Oxemia since its 2022 launch. Company-reported utilization requires independent validation, but it provides evidence of sustained prescribing outside a clinical-trial setting.

Japan established the regional HIF-PHI category earlier through roxadustat, including dialysis and later non-dialysis use. Indonesia’s approval of long-acting efepoetin alfa and China’s desidustat decision show that Asian competition is developing across both oral and injectable platforms.

Broader indications give Asian HIF-PHIs a higher patient ceiling than their U.S. counterparts. Uptake will still vary with reimbursement, physician confidence in cardiovascular safety, monitoring requirements, and the price of biosimilar ESAs.

 

Transfusion Use Exposes the Cost of Late Treatment

USRDS reported that nearly one in five U.S. patients with stage 4 or 5 CKD and haemoglobin below 9 g/dL received a red-blood-cell transfusion in 2023. More than three-quarters of transfused patients had not recently received an ESA. The registry cannot prove that earlier ESA or iron therapy would have prevented each transfusion, but it identifies a patient group reaching acute intervention without substantial exposure to established anemia treatment.

Transfusions generate hospital costs and create added risk for transplant candidates through allosensitization. KDIGO recommends basing transfusion decisions on clinical need rather than a fixed haemoglobin threshold and prioritizing avoidance among people who may receive a kidney transplant.

Earlier treatment could shift part of this spending into outpatient iron, ESA, HIF-PHI, and laboratory services. Suppliers that demonstrate transfusion avoidance will have a stronger payer argument than products supported only by mean haemoglobin change.

 

Hepcidin Programs Target Iron-Restricted and ESA-Hyporesponsive Patients

Standard treatment performs poorly in some patients because inflammation keeps hepcidin elevated and restricts usable iron. Escalating the ESA dose in this group increases cost without reliably correcting the underlying iron block.

Disc Medicine’s DISC-0974 targets hemojuvelin to suppress hepcidin. A completed Phase Ib study in non-dialysis CKD showed substantial hepcidin reductions, increased serum iron, and improved markers of erythropoiesis, but meaningful haemoglobin gains occurred only in a subset of patients. Higher baseline erythropoietin appeared to identify better responders.

The variable response narrows the commercial thesis. DISC-0974 may require biomarker selection rather than broad CKD-anemia use. Development value will depend on identifying patients with inflammation-driven iron restriction who remain anemic despite iron treatment or who require high ESA doses.

Modus Therapeutics is testing sevuparin in CKD-related anemia after completing the first part of a Phase IIa program in 2025. The program remains early and cannot yet support a treatment claim, but it provides a second industry effort aimed at hepcidin biology rather than direct erythropoietin replacement.

Hepcidin-targeted assets will need to demonstrate reduced ESA exposure, fewer transfusions, or reliable response in a defined population. Biomarker evidence without a measurable treatment-saving effect will not be enough to compete with established iron and ESA protocols.

 

Regional Market Direction

North America remains the largest organized dialysis-treatment market, but U.S. growth is constrained by bundled reimbursement and HIF-PHI labels limited to dialysis. Vafseo’s revenue and prescriber gains show that a new oral product can penetrate the system when dialysis organizations and reimbursement are secured. Jesduvroq’s withdrawal shows how quickly an approved product can fail without the same access structure.

Europe places greater weight on iron optimization, biosimilar competition, and conservative ESA targets. HIF-PHI uptake is likely to remain country-specific because national formularies assess cardiovascular uncertainty, administration savings, and acquisition cost differently.

Asia has the broader oral-treatment opportunity. China’s non-dialysis desidustat approval, India’s established Oxemia use, Japan’s multi-product HIF-PHI experience, and Indonesia’s long-acting ESA approval give the region several competing treatment models rather than one uniform transition away from ESAs.

Lower-income countries carry substantial CKD burden but have limited access to ferritin testing, intravenous infusion, dialysis, and branded oral drugs. Generic iron and epoetin products will retain volume leadership where treatment cost and infrastructure outweigh dosing convenience.

 

Competitive Positioning

Established ESA manufacturers retain the strongest position in haemodialysis because their products are embedded in facility protocols and procurement contracts. Their main pressure comes from biosimilar pricing, stricter haemoglobin targets, and iron strategies that reduce ESA dose.

Intravenous-iron suppliers gain when renal providers treat iron deficiency before escalating erythropoietic therapy. PIVOTAL and FIND-CKD give this segment stronger cardiovascular, ESA-sparing, and treatment-delay evidence than oral iron can offer in advanced disease.

Akebia has built the leading current U.S. HIF-PHI franchise through dialysis access and growing repeat prescribing. Zydus and CMS have opened the larger non-dialysis opportunity in China, while Astellas, FibroGen, Genexine, and regional partners have established earlier HIF-PHI and long-acting ESA platforms across Asian markets.

Disc Medicine and Modus Therapeutics represent the next competitive layer, but both must move beyond proof of mechanism. A successful hepcidin-directed therapy will require a defined responder population and evidence that iron mobilization reduces ESA dose, transfusion use, or treatment failure.

 

Analyst Insight

The Renal Anemia Treatment Market is expanding in two different directions. Dialysis remains the revenue anchor because treatment penetration, monitoring, and administration are already concentrated within organized providers. Growth within this segment will come from switching spend among ESAs, intravenous iron, and oral HIF-PHIs rather than from finding large numbers of untreated patients.

Non-dialysis CKD provides the larger patient ceiling but carries weaker diagnosis, lower treatment rates, and fragmented reimbursement. China’s desidustat approval shows how an oral drug can access that population when regulators permit broader use. U.S. labels currently prevent the same expansion.

The most important market indicators are iron-testing rates, ESA dose per patient, transfusion use, dialysis-contract coverage, HIF-PHI reimbursement after temporary add-on payments, non-dialysis approvals, and biomarker-defined response to hepcidin therapies. Suppliers that reduce total treatment burden will gain more than companies competing only on haemoglobin elevation.

 

Renal Anemia Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 6.29 Billion
Revenue Forecast in 2032	USD 9.84 Billion
Overall Growth Rate	CAGR of 6.6% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Application, By End User, By Geography
By Treatment Type	Erythropoiesis-Stimulating Agents, Iron Supplements (Oral Iron, Intravenous Iron), HIF-Prolyl Hydroxylase Inhibitors, Red Blood Cell Transfusions, Hepcidin-Targeted and Anti-Inflammatory Therapies, Other Supportive Treatments
By Application	Non-Dialysis-Dependent Chronic Kidney Disease, Hemodialysis-Dependent Chronic Kidney Disease, Peritoneal Dialysis-Dependent Chronic Kidney Disease, ESA-Hyporesponsive Renal Anemia, Iron-Deficiency and Iron-Restricted Renal Anemia
By End User	Hospitals, Dialysis Centers, Nephrology Clinics, Ambulatory Infusion Centers, Homecare Settings, Retail and Specialty Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Growing prevalence of chronic kidney disease and renal anemia, increasing demand for advanced anemia management therapies, rising adoption of innovative treatments targeting erythropoiesis and iron regulation
Customization Option	Available upon request